Use of Amivantamab to Treat Head and Neck Cancer

A method of treating recurrent or metastatic head and neck squamous cell carcinoma in a subject in need thereof comprising administering a therapeutically effective amount of the anti-EGFR/anti-cMet antibody (e.g., amivantamab), pembrolizumab, and carboplatin, wherein the subject is treatment-naïve in a recurrent/metastatic head and neck cancer setting, wherein the anti-EGFR/anti-cMet antibody is administered in 21-day cycles (i) in an amount of 1,600 mg if the subject has a body weight of less than 80 kg (or an amount of 2,240 mg if the subject has a body weight of ≥80 kg) on Cycle 1 Day 1, and then (ii) in an amount of 2,400 mg if the subject has a body weight of less than 80 kg (or an amount of 3,360 mg if the subject has a body weight of ≥80 kg) once weekly (Q1W) for the remainder of Cycle 1 (Days 8 and 15) and once every 3 weeks (Q3W) from Cycle 2 onwards, and wherein the pembrolizumab is administered at a dose of 200 mg Q3W (on Day 1 of each 21-day cycle) starting in Cycle 1 (e.g., as an intravenous injection), and wherein the carboplatin is administered at a dose of AUC 5 mg/mL·min Q3W (on Day 1 of each 21-day cycle) starting in Cycle 1 (e.g., as an intravenous injection).